Latest news with #Dx
Business Wire
3 days ago
- Business
- Business Wire
Scipher Medicine Announces Collaboration with Top-Three Pharmaceutical Company to Integrate Precision Medicine into Clinical Trial Design
BUSINESS WIRE)--Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, today announced a strategic collaboration with a top 3 global pharmaceutical company. The partnership aims to enhance clinical trials by incorporating PrismRA®, Scipher's proprietary precision medicine diagnostic, into an ongoing trial. PrismRA is designed to analyze a patient's molecular profile to predict non-response to certain therapies, enabling a more precise understanding of patient populations. By applying PrismRA within the context of this clinical trial, Scipher Medicine will provide critical insights into therapy response segmentation. These insights are expected to help refine patient selection strategies, better characterize treatment effects across subpopulations, and inform the design of future studies. This collaboration highlights the growing recognition of the value of precision medicine diagnostics in enhancing the efficiency and effectiveness of the drug development lifecycle. By prospectively or retrospectively analyzing patient data using advanced molecular tools like PrismRA, pharmaceutical companies can gain deeper biological insights that may substantially de-risk and accelerate the path from clinical trial to patient benefit. "We are incredibly pleased to partner with one of the world's leading pharmaceutical companies to embed precision medicine insights directly into their clinical trial process," said Reg Seeto, CEO of Scipher Medicine. "This collaboration exemplifies our commitment to driving precision medicine into drug development. By applying our validated diagnostic capabilities like PrismRA, we aim to help our partners better understand therapy response, optimize trial design, and ultimately bring the right therapies to the right patients more efficiently." Scipher Medicine leverages a robust suite of capabilities, including its AI-driven target selection and ranking methodologies, therapy response/non-response biomarker and diagnostic development, and its industry-leading clinico-transcriptomic data asset, to drive innovation across the entire therapeutic development spectrum. This partnership is a testament to the increasing adoption of these advanced approaches by leaders in the pharmaceutical industry. The specific terms of the collaboration were not disclosed. About Scipher Medicine Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology, and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico- genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients. For more information, please visit About PrismRA® PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual's molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world's largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit
Yahoo
3 days ago
- Business
- Yahoo
Scipher Medicine Announces Collaboration with Top-Three Pharmaceutical Company to Integrate Precision Medicine into Clinical Trial Design
Partnership integrates Scipher's PrismRA to deliver insights into therapy response segmentation WALTHAM, Mass., June 11, 2025--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, today announced a strategic collaboration with a top 3 global pharmaceutical company. The partnership aims to enhance clinical trials by incorporating PrismRA®, Scipher's proprietary precision medicine diagnostic, into an ongoing trial. PrismRA is designed to analyze a patient's molecular profile to predict non-response to certain therapies, enabling a more precise understanding of patient populations. By applying PrismRA within the context of this clinical trial, Scipher Medicine will provide critical insights into therapy response segmentation. These insights are expected to help refine patient selection strategies, better characterize treatment effects across subpopulations, and inform the design of future studies. This collaboration highlights the growing recognition of the value of precision medicine diagnostics in enhancing the efficiency and effectiveness of the drug development lifecycle. By prospectively or retrospectively analyzing patient data using advanced molecular tools like PrismRA, pharmaceutical companies can gain deeper biological insights that may substantially de-risk and accelerate the path from clinical trial to patient benefit. "We are incredibly pleased to partner with one of the world's leading pharmaceutical companies to embed precision medicine insights directly into their clinical trial process," said Reg Seeto, CEO of Scipher Medicine. "This collaboration exemplifies our commitment to driving precision medicine into drug development. By applying our validated diagnostic capabilities like PrismRA, we aim to help our partners better understand therapy response, optimize trial design, and ultimately bring the right therapies to the right patients more efficiently." Scipher Medicine leverages a robust suite of capabilities, including its AI-driven target selection and ranking methodologies, therapy response/non-response biomarker and diagnostic development, and its industry-leading clinico-transcriptomic data asset, to drive innovation across the entire therapeutic development spectrum. This partnership is a testament to the increasing adoption of these advanced approaches by leaders in the pharmaceutical industry. The specific terms of the collaboration were not disclosed. About Scipher Medicine Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology, and proprietary data, through our SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico- genomic data asset and biobank in addition to EMR data for over 3 million rheumatology patients. For more information, please visit About PrismRA® PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual's molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world's largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit View source version on Contacts Jaclyn Sign in to access your portfolio
Malaysian Reserve
24-04-2025
- Business
- Malaysian Reserve
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C., April 23, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments. 'Labcorp is dedicated to providing oncologists with a comprehensive portfolio of innovative solutions that enable precise, timely and personalized treatment decisions,' said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. 'With the expansion of our portfolio to include Labcorp Plasma Detect for clinical use and the availability of PGDx elio plasma focus Dx to support patient treatment selection, we're advancing care across the oncology spectrum, solidifying our commitment to transforming cancer diagnostics and improving patient outcomes.' Labcorp Plasma Detect: Advanced Risk Assessment for Colon Cancer PatientsStage III colon cancer has a nearly 30% recurrence rate within five years. Labcorp Plasma Detect is a blood-based test using whole-genome sequencing (WGS) to detect circulating tumor DNA (ctDNA), indicating the presence of molecular residual disease (MRD).i Patients who are MRD-positive after cancer treatment have a higher risk of recurrence and a poorer prognosis. Labcorp's test detects cancer recurrence risk that conventional methods might miss, helping to identify patients who could benefit from additional treatment or therapy. Key Features of Labcorp Plasma Detect: The test is Labcorp's first tumor-informed MRD solution for clinical use to support recurrence risk stratification. Labcorp Plasma Detect launched in 2024 for biopharma use to support exploratory and investigational studies. The test combines a WGS approach, without the need for a bespoke panel, with proprietary bioinformatics to deliver ctDNA detection down to a limit of detection (LOD95) of 0.005%. Results are available approximately 14 days after Labcorp receives the initial sample, and seven days for subsequent monitoring time points for each patient. Labcorp Plasma Detect is currently being evaluated in more than 10 clinical studies in the U.S. and internationally to assess MRD across various cancer types. Labcorp Plasma Detect will be offered initially through an Early Experience Program, with the intent to expand availability more broadly. PGDx elio plasma focus Dx Now Available for Use to Aid in Treatment SelectionPGDx elio plasma focus Dx is the first and only kitted pan-solid tumor liquid biopsy test to receive De Novo authorization from the FDA. This assay provides oncologists with a validated tool to assess various solid tumors for targeted treatment selection – all from a simple blood draw. Key Features of PGDx elio plasma focus Dx: The kitted model allows clinical laboratories and hospitals to retain control over patient specimens and data for research, care management and other clinical purposes. As an FDA-authorized assay, PGDx elio plasma focus Dx requires only on-site verification – as opposed to a full validation – enabling more rapid implementation. Once implemented, this rapid, scalable liquid biopsy genomic test provides actionable findings within a 4-to-5-day turnaround time, from isolated nucleic acid to variant report. As part of the PGDx elio platform, the kitted model is compatible with FDA-cleared PGDx elio™ tissue complete, enabling seamless, in-house tissue-to-liquid reflexing and efficient comprehensive genomic profiling workflows. Labcorp at the American Association for Cancer Research (AACR) 2025 Annual MeetingLabcorp will present key studies at the AACR 2025 Annual Meeting, including the clinical use of Labcorp Plasma Detect and performance of PGDx elio plasma focus Dx. To learn more, or to connect with Labcorp at AACR in Chicago, visit For more information about Labcorp's Oncology solutions, contact us at About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at i The term MRD is often used interchangeably between molecular residual disease and minimal residual disease. Labcorp Plasma Detect detects molecular residual disease, which is defined as the subclinical presence of a cancer-associated biomarker indicating a high risk of recurrence, which cannot be detected by standard imaging techniques. MRD terminology is in accordance with the BLOODPAC Consortium.
Globe and Mail
13-02-2025
- Business
- Globe and Mail
Drug Screening Market worth $19.5 billion by 2029
Labcorp (US): Labcorp is a leading player in the US drug screening services market that provides clinical laboratory services and drug development solutions. The company operates through two reportable segments—Diagnostics Laboratories (Dx), which includes routine testing and specialty/esoteric testing, and Biopharma Laboratory Services (BLS), consisting of Early Development Research Laboratories and Central Laboratory Services. The global drug screening market, valued at US$7.7 billion in 2023, is forecasted to grow at a robust CAGR of 16.6%, reaching US$9.1 billion in 2024 and an impressive US$19.5 billion by 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Some of the key factors such as the enforcement of stringent laws mandating drug & alcohol testing, the rising drug & alcohol consumption are driving the market. However, bans on alcohol consumption in Islamic countries may restrain the growth of this market to a certain extent. Browse in-depth TOC on "Drug Screening Market" 740 - Tables 62 - Figures 533 - Pages Services segment is expected to grow at the highest CAGR during the forecast period in 2024. On the basis of product & service segment, the drug screening market is bifurcated into services and products. In 2023, the services segment accounted for the largest share of the drug screening market. Factors such as rising global drug and alcohol consumption, funding schemes for drug testing laboratories, and rising regulatory approvals for drug products & services, and geographic extensions of drug & alcohol testing laboratories. Analytical instruments are projected to dominate the drug screening products market in 2023, by product. On the basis of drug screening product, the drug screening market is bifurcated into analytical instruments, rapid testing devices, and consumables. The analytical instruments are expected to dominate the market in 2023. However, the rapid testing devices segment is expected to register the highest CAGR during the forecast period, owing to its recurring requirement. Analytical instruments for drug screening are further categorized into immunoassay analyzers, chromatography instruments, and breathalyzers. The breathalyzers segment accounted for largest share of the drug screening products market, by analytical instruments. Urine sample segment is accounted for the largest share of the drug screening market in 2023, by sample type. On the basis of sample type, drug screening market is bifurcated into urine, breath, oral fluid, hair, and other samples. In 2024, the urine sample segment is expected to account for the largest share of drug screening market. Urine tests are widely adopted in drug screening tests due to their accuracy in detecting multiple drug classes. Urine tests are also cost-effective and showcase instant results. By region, North America to dominate the market for drug screening in 2024 In 2024, North America is projected to dominate the market followed by Europe. Factors such as the increasing consumption of illicit drugs, the increasing burden of accidents due to alcohol impairment, the availability of government funding to curb drug abuse, laws supporting drug screening, and the existence of key players in the region are factors driving the growth of the drug screening market in this region. The primary interviews conducted for this report can be categorized as follows: By Company Type - Tier 1: 57%, Tier 2: 30%, and Tier 3: 13% By Designation - C-level: 30%, D-level: 45%, and Others: 25% By Region - North America: 40%, Europe: 19%, Asia Pacific: 29%, Latin America: 7% and Middle East and Africa: 5% Key Market Players of Drug Screening Industry: Prominent players offering drug screening products and services include Labcorp (US), Quest Diagnostics (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Alfa Scientific Designs, Inc. (US), OraSure Technologies Inc. (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), MPD Inc. (US), Shimadzu Corporation (Japan), Lifeloc Technologies, Inc. (US), Drägerwerk AG & Co. KGaA (Germany), Premier Biotech, Inc. (US), Omega Laboratories, Inc. (US), Psychemedics Corporation (US), Clinical Reference Laboratory, Inc. (US), American Bio Medica Corporation (US), ACM Global Laboratories (US), CareHealth America Corp (US), Sciteck, Inc. (US), Intoximeters, Inc. (US), AccuSourceHR, Inc. (US), Cordant Health Solutions (US), Intoxalock (US), Millennium Health (US). Labcorp (US): Labcorp is a leading player in the US drug screening services market that provides clinical laboratory services and drug development solutions. The company operates through two reportable segments—Diagnostics Laboratories (Dx), which includes routine testing and specialty/esoteric testing, and Biopharma Laboratory Services (BLS), consisting of Early Development Research Laboratories and Central Laboratory Services. The company's Diagnostics Laboratories (Dx) segment offers drug and alcohol testing services. The company has more than 67,000 employees serve clients in over 100 countries, worked on over 84% of the new drugs approved by the FDA in 2023 and executed more than 600 million tests for patients around the world. The company has more than 80,000 employees, serves clients in more than 100 countries. Recently, in 2024 Labcorp announces acquisition of select assets of BioReference Health's diagnostic business expanding access to the company high-quality clinical laboratory services. Abbott (US): Abbott is one of the global providers of rapid, point of care tests and leader in drug screening market. Abbott operates via five business segments: Established Pharmaceuticals Products, Nutritional Products, Diagnostic Products, & Medical Devices. The Diagnostic products include sales of diagnostic systems tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The company provides drug screening products and services through the diagnostic products segment. The company's Diagnostics Product is further segmented into Core Laboratory, Rapid Diagnostics, Molecular, and Point of care. The company has a strong presence in North America, Europe, Asia Pacific, Latin America, & Middle East & Africa. The company provide substance abuse testing products and services for a array of settings such as rehabilitation centers,hospitals, criminal justice agencies, physician offices, workplace, and occupational health clinics, and homes.
